Rh family C glycoproteinGenealiases: C15orf6 · PDRC2 · RHGK · SLC42A3
Q-omics provides the consensus-scored RHCG profile across patient tissues and cancer cell-line models. RHCG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RHCG is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RHCG RNA expression shows 15,170 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where RHCG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHCG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHCG survival associations across molecular data types. RHCG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHCG RNA expression–survival associations across cancer types. High RHCG expression shows unfavorable associations in LUAD, MESO, KIRC and SKCM, but favorable associations in KICH and UVM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RHCG RNA expression.
This table summarizes RHCG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RHCG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHCG shows lower tumor expression in KIRC, KIRP and HNSC and higher tumor expression in COAD, LUSC and UCEC. The KIRC box plot shows higher RHCG RNA expression in normal versus tumor tissue (log2 FC = −6.551, t-test p < 0.001).
This table shows molecular features associated with RHCG in patient tissues and cancer cell lines. In patient samples, RHCG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHCG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
